ASX:IDX

Integral Diagnostics Competitors

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume240,828 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend Yield1.96%
BetaN/A

Competitors

Integral Diagnostics (ASX:IDX) Vs. BUX, IME, BD1, CRL, CTE, and DVL

Should you be buying IDX stock or one of its competitors? Companies in the industry of "diagnostics & research" are considered alternatives and competitors to Integral Diagnostics, including (BUX) (BUX), 12144 (IME), BARD1 Life Sciences (BD1), Charles River Laboratories International (CRL), Cryosite (CTE), and dorsaVi (DVL).

Integral Diagnostics (ASX:IDX) and (BUX) (CNSX:BUX) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, institutional ownership and valuation.

Earnings & Valuation

This table compares Integral Diagnostics and (BUX)'s revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Integral Diagnostics$314.82 million0.00$32.18 millionA$0.16N/A
(BUX)N/AN/AN/AN/AN/A

Integral Diagnostics has higher revenue and earnings than (BUX).

Profitability

This table compares Integral Diagnostics and (BUX)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Integral DiagnosticsN/AN/AN/A
(BUX)N/AN/AN/A

Analyst Ratings

This is a breakdown of recent recommendations for Integral Diagnostics and (BUX), as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Integral Diagnostics0000N/A
(BUX)0000N/A

Summary

Integral Diagnostics beats (BUX) on 1 of the 1 factors compared between the two stocks.

12144 (CNSX:IME) and Integral Diagnostics (ASX:IDX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.

Analyst Ratings

This is a breakdown of recent recommendations for 12144 and Integral Diagnostics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
121440000N/A
Integral Diagnostics0000N/A

Profitability

This table compares 12144 and Integral Diagnostics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
12144N/AN/AN/A
Integral DiagnosticsN/AN/AN/A

Earnings & Valuation

This table compares 12144 and Integral Diagnostics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
12144N/AN/AN/AN/AN/A
Integral Diagnostics$314.82 million0.00$32.18 millionA$0.16N/A

Integral Diagnostics has higher revenue and earnings than 12144.

Summary

Integral Diagnostics beats 12144 on 1 of the 1 factors compared between the two stocks.

BARD1 Life Sciences (ASX:BD1) and Integral Diagnostics (ASX:IDX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk and institutional ownership.

Valuation & Earnings

This table compares BARD1 Life Sciences and Integral Diagnostics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BARD1 Life Sciences$612,251.000.00$-6,644,706.43A($0.08)N/A
Integral Diagnostics$314.82 million0.00$32.18 millionA$0.16N/A

Integral Diagnostics has higher revenue and earnings than BARD1 Life Sciences.

Profitability

This table compares BARD1 Life Sciences and Integral Diagnostics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BARD1 Life SciencesN/AN/AN/A
Integral DiagnosticsN/AN/AN/A

Analyst Recommendations

This is a summary of recent recommendations and price targets for BARD1 Life Sciences and Integral Diagnostics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BARD1 Life Sciences0000N/A
Integral Diagnostics0000N/A

Summary

Integral Diagnostics beats BARD1 Life Sciences on 3 of the 3 factors compared between the two stocks.

Charles River Laboratories International (CNSX:CRL) and Integral Diagnostics (ASX:IDX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk and analyst recommendations.

Valuation & Earnings

This table compares Charles River Laboratories International and Integral Diagnostics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Charles River Laboratories InternationalN/AN/AN/AN/AN/A
Integral Diagnostics$314.82 million0.00$32.18 millionA$0.16N/A

Integral Diagnostics has higher revenue and earnings than Charles River Laboratories International.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Charles River Laboratories International and Integral Diagnostics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Charles River Laboratories International0000N/A
Integral Diagnostics0000N/A

Profitability

This table compares Charles River Laboratories International and Integral Diagnostics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Charles River Laboratories InternationalN/AN/AN/A
Integral DiagnosticsN/AN/AN/A

Summary

Integral Diagnostics beats Charles River Laboratories International on 1 of the 1 factors compared between the two stocks.

Integral Diagnostics (ASX:IDX) and Cryosite (ASX:CTE) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

Valuation & Earnings

This table compares Integral Diagnostics and Cryosite's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Integral Diagnostics$314.82 million0.00$32.18 millionA$0.16N/A
Cryosite$9.71 million0.00$515,455.60A$0.01N/A

Integral Diagnostics has higher revenue and earnings than Cryosite.

Profitability

This table compares Integral Diagnostics and Cryosite's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Integral DiagnosticsN/AN/AN/A
CryositeN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings for Integral Diagnostics and Cryosite, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Integral Diagnostics0000N/A
Cryosite0000N/A

Summary

Integral Diagnostics beats Cryosite on 3 of the 3 factors compared between the two stocks.

Integral Diagnostics (ASX:IDX) and dorsaVi (ASX:DVL) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations and risk.

Earnings and Valuation

This table compares Integral Diagnostics and dorsaVi's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Integral Diagnostics$314.82 million0.00$32.18 millionA$0.16N/A
dorsaVi$1.65 million0.00$-3,158,396.93A($0.01)N/A

Integral Diagnostics has higher revenue and earnings than dorsaVi.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Integral Diagnostics and dorsaVi, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Integral Diagnostics0000N/A
dorsaVi0000N/A

Profitability

This table compares Integral Diagnostics and dorsaVi's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Integral DiagnosticsN/AN/AN/A
dorsaViN/AN/AN/A

Summary

Integral Diagnostics beats dorsaVi on 3 of the 3 factors compared between the two stocks.


Integral Diagnostics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
BUX
(BUX)
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
IME
12144
0.5N/AN/AC$0.00N/A0.00High Trading Volume
Gap Down
BD1
BARD1 Life Sciences
0.5N/AN/A$0.00$612,251.000.00High Trading Volume
Gap Up
CRL
Charles River Laboratories International
0.5N/AN/A$0.00N/A0.00Gap Up
CTE
Cryosite
0.6N/AN/A$0.00$9.71 million0.00High Trading Volume
Gap Up
DVL
dorsaVi
0.5N/AN/A$0.00$1.65 million0.00High Trading Volume
Gap Up
Epigenomics logo
EPGNY
Epigenomics
0.6$12.39flat$0.00N/A0.00
ETAH
Eternity Healthcare
0.6$0.00flat$0.00N/A0.00
GSS
Genetic Signatures
0.0N/AN/A$0.00$29.13 million0.00High Trading Volume
GTG
Genetic Technologies
0.0N/AN/A$0.00$25,714.000.00High Trading Volume
IBX
Imagion Biosystems
0.6N/AN/A$0.00$2.70 million0.00High Trading Volume
Gap Up
LSH
Lifespot Health
0.5N/AN/A$0.00$22,127.000.00High Trading Volume
Gap Up
MEDD
Medical Imaging
0.4$0.01flat$0.00N/A0.00Gap Down
OSL
OncoSil Medical
0.5N/AN/A$0.00$2.22 million0.00High Trading Volume
Gap Up
Parallax Health Sciences logo
PRLX
Parallax Health Sciences
0.5$0.01flat$0.00N/A0.00Gap Down
RHY
Rhythm Biosciences
0.0N/AN/A$0.00$1.21 million0.00High Trading Volume
Sartorius Aktiengesellschaft logo
SRT3
Sartorius Aktiengesellschaft
0.6$469.80flat$0.00N/A0.00High Trading Volume
SENS
Senseonics
0.0N/AN/A$0.00N/A0.00High Trading Volume
SENS
Senseonics
0.0N/AN/A$0.00N/A0.00High Trading Volume
Siemens Healthineers logo
SMMNY
Siemens Healthineers
0.5$28.35flat$0.00N/A0.00
SIL
Smiles Inclusive
0.4N/AN/A$0.00$36.48 million0.00High Trading Volume
Gap Up
VHT
Volpara Health Technologies
0.5N/AN/A$0.00$15.22 million0.00High Trading Volume
News Coverage
Gap Up
OBJ
Wellfully Limited (OBJ.AX)
0.0N/AN/A$0.00$1.48 million0.00High Trading Volume
WUXIF
WuXi AppTec
1.0$19.88flat$0.00N/A0.00
This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.